TY  - EJOU
AU  - Burg, Daniel 
AU  - Babkoff, Aryeh 
AU  - Or, Omer 
AU  - Olshinka, Noam 
AU  - Demma, Jonathan Abraham 
AU  - Adila, Mohamad 
AU  - Wygoda, Marc 
AU  - Blumenfeld, Philip 
AU  - Diment, Judith 
AU  - Galiner, Masha 
AU  - Azraq, Yusef 
AU  - Katz, Daniela 
AU  - Reissman, Petachia 
AU  - Ostrowicki, Sadie 
AU  - Sebbag, Gabriella 
AU  - Elkhateeb, Narmine 
AU  - Moshe, Anat Hershko 
AU  - Jaber, Dania 
AU  - Hollander, Adi 
AU  - Rubin, Limor 
AU  - Zick, Aviad 

TI  - BRAF<sup><b>V600E</b></sup> Metastatic Synovial Sarcoma Treated with BRAF \& MEK Inhibitors Achieves Complete Response. A Case Report \& Literature Review
T2  - Oncology Research

PY  - 2026
VL  - 34
IS  - 4
SN  - 1555-3906

AB  -  <b>Background:</b> —Synovial sarcoma is a rare soft tissue sarcoma. Treatment of synovial sarcoma includes surgery, radiation, pazopanib, and chemotherapy. Targeted therapies, such as B-Raf proto-oncogene, serine/threonine kinase (BRAF) inhibitors, are emerging as a potential treatment option. We describe the sixth case of a BRAF<sup>V600E</sup> synovial sarcoma, the first extra-thoracic case. This case is the first to show a complete pathological response to BRAF &amp; mitogen-activated protein kinase kinase (MEK) inhibitors. <b>Case description:</b> —We treated a 22-year-old male with a left groin BRAF<sup>V600E</sup> synovial sarcoma with doxorubicin, Ifosphamide &amp; Sodium 2-Mercaptoethanesulfonate. When we identified BRAF<sup>V600E</sup> in the tumor, the BRAF<sup>V600E</sup> and MEK inhibitors (dabrafenib &amp; trametinib) were initiated, followed by surgery, with a complete pathological response. Nine months after the surgery, a local recurrence prompted the resumption of dabrafenib &amp; trametinib followed by radiotherapy, resulting in complete radiological response and the development of hemophagocytic lymphohistiocytosis treated with corticosteroids with resolution of symptoms. <b>Conclusion:</b> —Panel sequencing of synovial sarcoma can identify targetable mutations. Treatment of BRAF<sup>V600E</sup> synovial sarcoma with dabrafenib &amp; trametinib can lead to complete pathological response and prolonged radiological response, as well as the rare adverse event of hemophagocytic lymphohistiocytosis. Prospective clinical trials are needed to evaluate the efficacy and safety of BRAF<sup>V600E</sup> &amp; MEK inhibitors as a therapeutic approach in BRAF<sup>V600E</sup> synovial sarcoma.
KW  - Synovial sarcoma; B-Raf proto-oncogene; serine/threonine kinase<sup>V600E</sup>; serine/threonine kinase inhibitor; mitogen-activated protein kinase kinase inhibitor; case report

DO  - 10.32604/or.2026.070233